IL-17A/IL-17RA interaction promoted metastasis of osteosarcoma cells

Cancer Biology and Therapy

Volumn 14, Issue 2, 2013, Pages 155-163

  Wang, Mingmin ^a   Wang, Luanqiu ^b   Ren, Tao ^c   Xu, Lin ^d   Wen, Zhenke ^e  

^a Qingdao Blood Center   (China)

^b Qingdao Cancer Hospital   (China)

^c TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^d ZUNYI MEDICAL UNIVERSITY   (China)

^e FUDAN UNIVERSITY   (China)

Author keywords

IL 17A; IL 17RA; Metastasis; Osteosarcoma

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CYTOKINE; GELATINASE B; INTERLEUKIN 17; INTERLEUKIN 17RA; STAT3 PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADOLESCENT; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; LUNG METASTASIS; MALE; METASTASIS; MOUSE; NONHUMAN; OSTEOSARCOMA CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; UPREGULATION;

IL-17A; IL-17RA; METASTASIS; OSTEOSARCOMA;

ADOLESCENT; ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; CHILD; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-17; MALE; MATRIX METALLOPROTEINASE 9; MICE; NEOPLASM METASTASIS; OSTEOSARCOMA; PROTEIN BINDING; RECEPTORS, CXCR4; RECEPTORS, INTERLEUKIN-17; STAT3 TRANSCRIPTION FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTORS; YOUNG ADULT;

EID: 84873451530     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.22955     Document Type: Article

References (37)

1. Ma O, Cai WW, Zender L, Dayaram T, Shen J, Herron AJ, et al. MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. Cancer Res 2009; 69:2559-67; PMID:19276372; http://dx.doi.org/10.1158/0008-5472.CAN-08-2929.
2. Yan K, Gao J, Yang T, Ma Q, Qiu X, Fan Q, et al. MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PLoS One 2012; 7:e33778; PMID:22457788; http://dx.doi.org/10.1371/journal. pone.0033778.
3. Walkley CR, Qudsi R, Sankaran VG, Perry JA, Gostissa M, Roth SI, et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev 2008; 22:1662-76; PMID:18559481; http://dx.doi.org/10.1101/gad.1656808.
4. Ando K, Mori K, Verrecchia F, Marc B, Rédini F, Heymann D. Molecular alterations associated with osteosarcoma development. Sarcoma 2012; 2012:523432; PMID:22448123; http://dx.doi.org/10.1155/2012/523432.
5. Bacci G, Ferrari S, Longhi A, Perin S, Forni C, Fabbri N, et al. Pattern of relapse in patients with osteosarcoma of the extremities treated with neoadjuvant chemotherapy. Eur J Cancer 2001; 37:32-8; PMID:11165127; http://dx.doi.org/10.1016/S0959-8049(00)00361-0.
6. Paoloni M, Davis S, Lana S, Withrow S, Sangiorgi L, Picci P, et al. Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics 2009; 10:625; PMID:20028558; http://dx.doi.org/10. 1186/1471-2164-10-625.
7. Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 2008; 134:281-97; PMID:17965883; http://dx.doi.org/10.1007/s00432-007-0330-x.
8. Fossey SL, Bear MD, Kisseberth WC, Pennell M, London CA. Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines. BMC Cancer 2011; 11:125; PMID:21481226; http://dx.doi.org/10.1186/1471- 2407-11-125.
9. Bacci G, Longhi A, Cesari M, Versari M, Bertoni F. Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy: the experience of a single institution with 44 patients. Cancer 2006; 106:2701-6; PMID:16691623; http://dx.doi.org/10.1002/ cncr.21937.
10. Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev 2006; 32:423-36; PMID:16860938; http://dx.doi.org/10.1016/j.ctrv.2006.05.005.
11. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007; 25:821-52; PMID:17201677; http://dx.doi.org/10.1146/annurev.immunol.25.022106. 141557.
12. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009; 27:485-517; PMID:19132915; http://dx.doi.org/10.1146/annurev. immunol.021908.132710.
13. Kolls JK, Lindén A. Interleukin-17 family members and inflammation. Immunity 2004; 21:467-76; PMID:15485625; http://dx.doi.org/10. 1016/j.immuni.2004.08.018.
14. Bettelli E, Oukka M, Kuchroo VKT. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007; 8:345-50; PMID:17375096; http://dx.doi.org/10.1038/ni0407-345.
15. Martin-Orozco N, Dong C. The IL-17/IL-23 axis of inflammation in cancer: friend or foeCurr Opin Investig Drugs 2009; 10:543-9; PMID:19513943.
16. Ngiow SF, Smyth MJ, Teng MW. Does IL-17 suppress tumor growthBlood 2010; 115:2554-5, author reply 2556-7; PMID:20339108; http://dx.doi.org/10.1182/blood- 2009-11-254607.
17. Ji Y, Zhang W. Th17 cells: positive or negative role in tumorCancer Immunol Immunother 2010; 59:979-87; PMID:20352428; http://dx.doi.org/10.1007/ s00262-010-0849-6.
18. Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautès-Fridman C, et al. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002; 99:2114-21; PMID:11877287; http://dx.doi.org/10.1182/blood.V99.6.2114.
19. Hirahara N, Nio Y, Sasaki S, Minari Y, Takamura M, Iguchi C, et al. Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice. Oncology 2001; 61:79-89; PMID:11474253; http://dx.doi.org/10.1159/000055357.
20. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood 2003; 101:2620-7; PMID:12411307; http://dx.doi.org/10.1182/blood-2002-05-1461.
21. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009; 114:357-9; PMID:19289853; http://dx.doi.org/10.1182/blood-2008-09-177360.
22. Honorati MC, Cattini L, Facchini A. Possible prognostic role of IL-17R in osteosarcoma. J Cancer Res Clin Oncol 2007; 133:1017-21; PMID:17690908; http://dx.doi.org/10.1007/s00432-007-0296-8.
23. Bajpai J, Sharma M, Sreenivas V, Kumar R, Gamnagatti S, Khan SA, et al. VEGF expression as a prognostic marker in osteosarcoma. Pediatr Blood Cancer 2009; 53:1035-9; PMID:19621435; http://dx.doi.org/10.1002/pbc.22178.
24. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7:41-51; PMID:17186030; http://dx.doi.org/10.1038/nri1995.
25. Zhang X, Yue P, Page BD, Li T, Zhao W, Namanja AT, et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A 2012; 109:9623-8; PMID:22623533; http://dx.doi.org/10.1073/pnas.1121606109.
26. Lavecchia A, Di Giovanni C, Novellino E. STAT-3 inhibitors: state of the art and new horizons for cancer treatment. Curr Med Chem 2011; 18:2359-75; PMID:21568920; http://dx.doi.org/10.2174/092986711795843218.
27. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009; 206:1457-64; PMID:19564351; http://dx.doi.org/10.1084/jem.20090207.
28. Mantovani A. Role of inflammatory cells and mediators in tumor invasion and metastasis. Cancer Metastasis Rev 2010; 29:241; PMID:20397039; http://dx.doi.org/10.1007/s10555-010-9228-1.
29. Solinas G, Marchesi F, Garlanda C, Mantovani A, Allavena P. Inflammation-mediated promotion of invasion and metastasis. Cancer Metastasis Rev 2010; 29:243-8; PMID:20414701; http://dx.doi.org/10.1007/s10555-010-9227-2.
30. Danese S, Mantovani A. Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer. Oncogene 2010; 29:3313-23; PMID:20400974; http://dx.doi.org/10.1038/onc.2010.109.
31. Murugaiyan G, Saha B. Protumor vs antitumor functions of IL-17. J Immunol 2009; 183:4169-75; PMID:19767566; http://dx.doi.org/10.4049/jimmunol. 0901017.
32. Chen X, Xie Q, Cheng X, Diao X, Cheng Y, Liu J, et al. Role of interleukin-17 in lymphangiogenesis in non-small-cell lung cancer: Enhanced production of vascular endothelial growth factor C in non-small-cell lung carcinoma cells. Cancer Sci 2010; 101:2384-90; PMID:20825419; http://dx.doi.org/10.1111/j.1349-7006.2010.01684.x.
33. Ren T, Wen ZK, Liu ZM, Liang YJ, Guo ZL, Xu L. Functional expression of TLR9 is associated to the metastatic potential of human lung cancer cell: functional active role of TLR9 on tumor metastasis. Cancer Biol Ther 2007; 6:1704-9; PMID:17986857; http://dx.doi.org/10.4161/cbt.6.11.4826.
34. Wright JF, Bennett F, Li B, Brooks J, Luxenberg DP, Whitters MJ, et al. The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J Immunol 2008; 181:2799-805; PMID:18684971.
35. Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 2005; 175:6177-89; PMID:16237115.
36. Ren T, Xu L, Jiao S, Wang Y, Cai Y, Liang Y, et al. TLR9 signaling promotes tumor progression of human lung cancer cell in vivo. Pathol Oncol Res 2009; 15:623-30; PMID:19319670; http://dx.doi.org/10.1007/s12253-009-9162-0.
37. Deodhar SD, James K, Chiang T, Edinger M, Barna BP. Inhibition of lung metastases in mice bearing a malignant fibrosarcoma by treatment with liposomes containing human C-reactive protein. Cancer Res 1982; 42:5084-8; PMID:7139613.